 AVEO Oncology Nasdaq: AVEO today announced that it has priced its previously announced underwritten public offering of 8,500,000 shares of its common stock at a price to the public of 5.25 per share. The gross proceeds to AVEO from the offering are expected to be approximately 44.6 million before deducting underwriting discounts and commissions and offering expenses. All of the shares in the offering are being sold by AVEO. AVEO has also granted the underwriters a 30-day option to purchase up to an additional 1,275,000 shares of common stock on the same terms and conditions. Closing of the offering is expected to occur on or about June 19, 2020, subject to satisfaction of customary closing conditions. 